You are here: Services / Lyme Borreliosis / LTT / 
Deutsch
English

Borrelia Elispot-LTT (LymphocyteTransformationsTest)

Actual news: 

The Elispot-LTT method has been approved by the FDA in May 2011 for M. tuberculosis (Not ITT or MELISA) !!!

The FDA argues in this paper:

"... A positive result (in the Elispot-LTT) suggests that an infection is likely, a negative result that an infection is unlikely..."

"... Results (of the Elispot-LTT) can be available within 24 hours (ITT or MELISA not)..."

A Borrelia infection does not only activate the humoral immune response, but also activates T-lymphocytes at the same time.  Once Borrelia bacteria are not active anymore, the T-cellular immune response is not present.

It is not possible to test the treatment success by Borrelia antibodies, because the 'titer" or antibodies can be measured in the blood over years.  Furthermore, Lyme infections in Stage I (e.g. 'bulls-eye rash' or 'summer flu') only show antibodies in the blood after weeks and sometimes do not show them at all.

The Borrelia Elispot-LTT eliminates these problems.  The test reflects the actual, current Borrelia burgdorferi activity of chronic and also acute Lyme infections.  The Elispot-LTT is highly sensitive and can detect even one single Borrelia-reactive T-cell in the blood.  The Elispot-LTT is very helpful when monitoring a chronic or acute Lyme therapy.  The Elispot-LTT should usually become negative about 6 to 8 weeks after completion of an effective therapy.

 

Borrelia burgdorferi Elispot-LTT:

Material: 2 x 8.5 ml CPDA-Tubes (Do not centrifuge, keep at room temperature, do not cool or keep in a cool storage place)

Analytical test duration: 2 Days (Important remark: The laboratory report needs about 1 week because of additional pre- and postanalytical laboratory processes)

 Indication:

  • to diagnose chronic Lyme disease
  • to diagnose acute Lyme disease
  • to determine the duration of therapy
  • to monitor treatment results after a Lyme therapy

Infectolab offers beneath the Borrelia burgdorferi-Elispot-LTT following bacterial Elispot-LTT:

- Chlamydia pneumoniae-Elispot-LTT

- Chlamydia trachomatis-Elispot-LTT

- Ehrlichia/Anaplasma-Elispot-LTT

- Yersinia-Elispot-LTT

- Epstein Barr-Virus (EBV)-Elispot-LTT

Material: 1 x 8.5 ml CPDA-Tubes for each bacterial Elispot-LTT (Do not centrifuge, keep at room temperature, do not cool or keep in a cool storage place)

Analytical test duration: 2 Days (Important remark: The laboratory report needs about 1 week because of additional pre- and postanalytical laboratory processes)

Indication:

  • to diagnose active Chlamydia pneumoniae, Chlamydia trachomatis, Ehrlichia/Anaplasma, Yersinia, EBV infections
  • to determine the duration of therapies
  • to monitor treatment results therapies

Sensitivity, Specificity and diagnostic Quality of the Lymphocyte-Transformations-Tests

 Based on the displayed literature, the following tables show the diagnostic quality and effectiveness of the LTT as well as the sensitivity and specificity of the LTT.  (compare Tabel 1 and 2 -  click on the tables to enlarge them).

Publication about the Borrelia Lymphocyte-Transformations-Test (LTT) in chronological order, evaluated by the author.

 +     positive

(+)   positive with constraints (+/-) skeptical

(-)    negative

 * These tests are not done by Infectolab.

(Kopie 2)